Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

91.02EUR
9:30am EDT
Change (% chg)

€-0.49 (-0.54%)
Prev Close
€91.51
Open
€90.66
Day's High
€91.44
Day's Low
€90.64
Volume
28,067
Avg. Vol
92,618
52-wk High
€91.76
52-wk Low
€47.60

Latest Key Developments (Source: Significant Developments)

Oncodesign says option to license rights for Parkinson Program from Ipsen
Wednesday, 15 Mar 2017 12:45pm EDT 

Oncodesign Sa : Oncodesign announces return of research collaboration and option to license rights for parkinson program from Ipsen . Oncodesign recovers full rights to LRRK2 program and patent portfolio .Following reacquisition, Oncodesign now intends to pursue further development of LRRK2 based parkinson program internally.  Full Article

Ipsen says will update long term guidance "in the spring"
Thursday, 23 Feb 2017 04:36am EST 

Ipsen CEO David Meek says : group to focus on integrating assets, looking at strategic options "all the time" . oncology, urology and rare diseases areas of interest in the future . group to update long term guidance "in the spring" Further company coverage: [IPN.PA] (Paris Newsroom).  Full Article

Ipsen FY net profit rises to 226.6 million euros
Thursday, 23 Feb 2017 01:00am EST 

Ipsen SA : Delivers strong 2016 results and expects further sales growth and margin enhancement for 2017 . FY net profit EUR 226.6 million ($239.18 million) versus EUR 190.7 million year ago . FY group sales EUR 1.58 billion versus EUR 1.44 billion year ago . FY core operating income EUR 363.9 million versus EUR 327.7 million . Sees for 2017 specialty care sales growth year-on-year greater than +18.0%; . FY closing net cash reached EUR 68.6 million at the end of the period, compared to EUR 186.9 million in 2015 . Sees for 2017 primary care sales growth year-on-year greater than +4.0%; .Sees for 2017 core operating margin (excluding amortization of intangible assets) greater than 24% of net sales..  Full Article

Ipsen acquires a portfolio of select consumer healthcare products from Sanofi
Monday, 13 Feb 2017 01:52am EST 

Ipsen SA : Ipsen to acquire a portfolio of select consumer healthcare products from Sanofi . Ipsen to pay 83 million euros ($88.24 million) cash upon closing for products . Transaction, which is subject to customary closing conditions, including european commission's approval, is expected to close in Q2 of 2017 .Transaction will be fully financed by Ipsen's existing cash and lines of credit.  Full Article

Ipsen to acquire Primary Care Platform in Italy from Akkadeas Pharma
Tuesday, 31 Jan 2017 01:55am EST 

Ipsen SA : Ipsen to acquire Primary Care Platform in Italy from Akkadeas Pharma . Signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of company in future. .As part of transaction, Akkadeas Pharma will become Ipsen's Italian distributor for Smecta (Diosmectal).  Full Article

Ipsen to acquire Oncology Assets from Merrimack Pharmaceuticals
Sunday, 8 Jan 2017 07:45pm EST 

Ipsen Sa : Ipsen to acquire Oncology Assets from Merrimack Pharmaceuticals . Entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals, including its product ONIVYDE . Co to pay $575 million cash at closing plus upto $450 million upon approval of potential additional indications for ONIVYDE in the U.S. . Deal should be dilutive in 2017 and accretive from 2018 onwards both in operating margin and EPS .Transaction will be fully financed by Ipsen's existing cash and lines of credit.  Full Article

BRIEF-Exelixis and Ipsen amend exclusive licensing agreement for commercialization,development of Cabozantinib to include Canada
Wednesday, 21 Dec 2016 01:18am EST 

Exelixis Inc : Press release - Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include canada . Exelixis - Amendment enhances productive year with Cabometyx regulatory approvals and commercial launches in United States and European Union . Says Exelixis to receive $10 million upfront payment, with subsequent regulatory and commercial milestones . Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of Cabozantinib to include Canada . Says Ipsen is currently initiating launch of Cabometyx in EU .Says regulatory filing in canada is expected in 2017, with regulatory approval anticipated in early 2018.  Full Article

Ipsen and Exelixis receive positive CHMP opinion for Cabometyx
Friday, 22 Jul 2016 09:03am EDT 

Ipsen SA : Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx (cabozantinib) for treatment of advanced renal cell carcinoma in adults . Cabometyx (cabozantinib) significantly improved overall survival across all evaluated patient subgroups .Recommendation will now be reviewed by the European Commission with a decision expected two months post CHMP opinion.  Full Article

Ipsen says EMA accepts marketing authorization application for telotristat etiprate
Monday, 18 Jul 2016 12:00pm EDT 

Ipsen SA : Ipsen announces the acceptance by the european medicines agency of the marketing authorization application for telotristat etiprate to treat carcinoid syndrome caused by neuroendocrine tumors, in combination with somatostatin analogues .Ipsen will pursue a worldwide regulatory plan for marketing authorization submissions in territories where it operates.  Full Article

Ipsen SA says David Meek appointed as CEO
Monday, 11 Jul 2016 01:00am EDT 

Ipsen Sa : David Meek appointed as chief executive officer of Ipsen . CEO appointment effective july 18, 2016 . Marc De Garidel will assume role of non-executive chairman and will continue to serve board of directors .Most recently, David Meek was executive vice-president and president of oncology division of Baxalta.  Full Article

More From Around the Web

BRIEF-Ipsen announces Health Canada approval of dysport therapeutic for treatment of patients with cervical dystonia

* Ipsen announces health canada approval of dysport therapeutic™ (abobotulinumtoxina) for the treatment of patients with cervical dystonia and adult upper limb spasticity Source text for Eikon: Further company coverage: